22.418 articles found

Treatment of movement disorders with a metabotropic glutamate 4 receptor positive allosteric modulator

CONN P. J, DILELLA ANTHONY G, KINNEY GENE G, MARINO MICHAEL J, SEABROOK GUY R, WILLIAMS DAVID L.

· 2004-07-07

A case study in the treatment of dementia with Lewy bodies.

Kaufer DI.

Acta Psychiatr Scand · 2004-07-01

DOI: 10.1111/j.1600-0447.2004.00323.xPMID: 15180783

Selective blockade of D(3) dopamine receptors enhances the anti-parkinsonian properties of ropinirole and levodopa in the MPTP-lesioned primate.

Silverdale MA, Nicholson SL, Ravenscroft P, Crossman AR, Millan MJ, Brotchie JM.

Exp Neurol · 2004-07-01

DOI: 10.1016/j.expneurol.2004.03.022PMID: 15191809

Improvements in stable patients with psychotic disorders switched from oral conventional antipsychotics therapy to long-acting risperidone.

van Os J, Bossie CA, Lasser RA.

Int Clin Psychopharmacol · 2004-07-01

DOI: 10.1097/01.yic.0000122861.35081.16PMID: 15201570

Metals in our minds: therapeutic implications for neurodegenerative disorders.

Doraiswamy PM, Finefrock AE.

Lancet Neurol · 2004-07-01

DOI: 10.1016/s1474-4422(04)00809-9PMID: 15207800

Rotigotine monotherapy in early Parkinson's disease.

Morgan JC, Sethi KD.

Curr Neurol Neurosci Rep · 2004-07-01

DOI: 10.1007/s11910-004-0050-4PMID: 15217539

Ropinirole versus levodopa in Parkinson's disease.

Morgan JC, Sethi KD.

Curr Neurol Neurosci Rep · 2004-07-01

DOI: 10.1007/s11910-004-0051-3PMID: 15217540

[Gene therapy for Parkinson's disease].

Fraix V.

Rev Med Interne · 2004-07-01

DOI: 10.1016/j.revmed.2004.03.005PMID: 15219371

Group psychotherapy and Parkinson's disease: when members and therapist share the diagnosis.

Paparella LR.

Int J Group Psychother · 2004-07-01

DOI: 10.1521/ijgp.54.3.401.40336PMID: 15253511

Recent failures of new potential symptomatic treatments for Parkinson's disease: causes and solutions.

Linazasoro G.

Mov Disord · 2004-07-01

DOI: 10.1002/mds.20120PMID: 15254931

Spinocerebellar ataxia type 2 with Levodopa-responsive parkinsonism culminating in motor neuron disease.

Infante J, Berciano J, Volpini V, Corral J, Polo JM, Pascual J, Combarros O.

Mov Disord · 2004-07-01

DOI: 10.1002/mds.20090PMID: 15254952

Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.

Holloway RG, Shoulson I, Fahn S, Kieburtz K, Lang A, Marek K, McDermott M, Seibyl J, Weiner W, Musch B, Kamp C, Welsh M, Shinaman A, Pahwa R, Barclay L, Hubble J, LeWitt P, Miyasaki J, Suchowersky O, Stacy M, Russell DS, Ford B, Hammerstad J, Riley D, Standaert D, Wooten F, Factor S, Jankovic J, Atassi F, Kurlan R, Panisset M, Rajput A, Rodnitzky R, Shults C, Petsinger G, Waters C, Pfeiffer R, Biglan K, Borchert L, Montgomery A, Sutherland L, Weeks C, DeAngelis M, Sime E, Wood S, Pantella C, Harrigan M, Fussell B, Dillon S, Alexander-Brown B, Rainey P, Tennis M, Rost-Ruffner E, Brown D, Evans S, Berry D, Hall J, Shirley T, Dobson J, Fontaine D, Pfeiffer B, Brocht A, Bennett S, Daigneault S, Hodgeman K, O'Connell C, Ross T, Richard K, Watts A, Parkinson Study Group.

Arch Neurol · 2004-07-01

DOI: 10.1001/archneur.61.7.1044PMID: 15262734